Her2-neu: a target in lung cancer?

نویسندگان

  • F Andre
  • T Le Chevalier
  • J C Soria
چکیده

In addition to the steady flow of new cytotoxic drugs for lung cancer during the last decade, the elegant concept of targeted agents has in recent years become a source of optimism and pitfalls. Among all the targets, Her2-neu is a typical example of how preclinical data can be translated into clinical progress. Her2-neu in breast cancer: the ideal model Erb-B2 (Her2-neu) is a 185 kDa glycoprotein with tyrosine kinase activity. This protein is a member of the ErbB receptor family that also includes ErbB1 (EGFr), ErbB3 and ErbB4. The implication of Her2-neu in mammary carcinogenesis has been shown in vitro [1] and in vivo [2]. Since then, most of the studies focusing on ErbB2 have been carried out in breast cancer. In this model, it has been shown that ErbB2 overexpression was associated with poor prognosis in some subsets of patients [3, 4] and with tamoxifen resistance [5]. Since ErbB2 overexpression was involved in mammary carcinogenesis, the idea has emerged that its inhibition could lead to tumor regression. Monoclonal anti-ErbB2 antibodies have been developed in this setting. Preclinical studies that tested anti-Her2-neu antibodies have shown that (i) injection of mono-clonal anti-Her2neu antibodies induce tumor regressions in mice and (ii) the anti-Her2neu antibody induces tumor cell growth inhibition in vitro. Following these data, a humanized monoclonal antibody directed against Her2-neu (trastuzumab) has been tested in clinical trials. The pivotal trial was published in the New England Journal of Medicine in 2001 [6]. This randomized trial compared anthracycline-or taxane-based chemotherapy versus the same chemotherapy plus trastuzumab. The results showed that the addition of trastuzumab increased response rates (50% versus 34%), time to progression (7.4 versus 4.6 months) and overall survival (25 versus 20 months). Some technical and logistical considerations must be put forward. This trial included patients presenting weak to moderate Her2-neu overexpression (coded as 2+) and more than moderate Her2-neu overexpression (3+) in >10% of tumor cells while 70–80% of tumors were coded 3+. This restriction allowed the recruitment of 469 patients during a 2-year period. Encouraged by these exciting data, investigators have looked at potential indications of trastuzumab in other cancers, including non-small-cell lung cancer (NSCLC). Her2-neu in lung cancer: is the mammalian model adequate in bronchial tumors? Some studies have shown that a small subset of NSCLC over-express Her2-neu. Nevertheless, the exact percentage of Her2-neu overexpression in NSCLC is difficult to assess since papers report overexpression rates ranging …

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Determination of Soluble HER-2/neu (sHER-2/neu) in Iranian Patients with Lung Cancer

Background: The HER-2/neu gene is located on chromosome 17q21 and encodes a 185-kDa transmembrane glycoprotein with tyrosine kinase activity reported to be released in soluble form in various malignancies. Objective: To evaluate the clinical significance of soluble Her-2/neu as a diagnostic marker in lung cancer. Methods: Serum levels of soluble HER-2/neu were measured in 43 patients with lung ...

متن کامل

بررسی فراوانی جهش‌های مضاعف شدگی ژنHER2/neu در بیماران مبتلا به سرطان معده با استفاده از تکنیک تکثیر پروب وابسته به الحاق چندتایی

Background and aims:  Gastric malignancies have the fourth place among the most prevalent cancers. In many cancers, overexpressing of HER2/neu gene has been observed with a poor prediction. Up to now, there is a little information about the duplication of HER2/neu gene in gastric cancer using MLPA method. The present study aimed to investigate the frequency of mutations resulting from ampl...

متن کامل

HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.

Previously, we have reported a correlation between the expression of HER2/neu and sensitivity to HLA-A2-restricted cytotoxic T-cells (CTL) in ovarian cancer. To investigate the role of HER2/neu in human non-small cell lung cancer (NSCLC), we established autologous tumor-specific CTL from tumor-infiltrating lymphocytes of HLA-A2+ HER2/neu+ NSCLC patients. These CTL lines specifically recognized ...

متن کامل

HER2/neu peptide-based vaccines, with GM-CSF as an adjuvant, in patients with advanced-stage HER2/neu-expressing cancers.

Rationale Despite advances in surgery, chemo­ merapy, and radiation, paciems wim solid mmors such as breast, ovarian, or lung cancer may relapse because of residual microscopic disease. The identification ofseveral tumor amigens, such as HER2! neu and p53, and an increased under­ standing of the role rhey play in malig­ nam cransformation, have led to clinical studies evaluaring antigen-specifi...

متن کامل

بررسی ارتباط بین مارکرهای سرمی HER2-neu،CA15-3 و CEA در بیماران کانسر پستان با مرحله تومور

    Background & Aims : This study aimed to explore the correlation of serum level of HER2-neu, CA 15-3, and CEA with TNM staging for breast cancer   Material & Methods : In this study serum samples of 50 patients with breast cancer were assessed with ELISA method for level of HER2-neu, CA15-3 and CEA preoperatively. After operation histopathologic specimens stained with Hematoxylin and E...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Annals of oncology : official journal of the European Society for Medical Oncology

دوره 15 1  شماره 

صفحات  -

تاریخ انتشار 2004